912273-65-5

Basic information

• Product Name: Edoxaban
• Synonyms: N-(5-Chloro-2-pyridinyl)-N'-[4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide 4-methylbenzenesulfonate (1:1);CL068
• CAS NO: 912273-65-5
• Molecular Formula: C24H30ClN7O4S
• Molecular Weight: 548.0575
• Product Categories: API;Inhibitors
• Mol File: 912273-65-5.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• Density: 1.43
• CAS DataBase Reference: Edoxaban(CAS DataBase Reference)
• NIST Chemistry Reference: Edoxaban(912273-65-5)
• EPA Substance Registry System: Edoxaban(912273-65-5)

Safety Data

• Hazardous Substances Data: 912273-65-5(Hazardous Substances Data)

Usage

Description

Edoxaban is a direct oral anticoagulant medication that selectively inhibits the activation of Factor Xa, a key enzyme in the blood clotting process. It is characterized by a rapid onset of action, a relatively long half-life, and does not require routine monitoring of coagulation levels, making it a convenient and effective alternative to other anticoagulants.

Uses

Used in Cardiology:
Edoxaban is used as an anticoagulant for patients with atrial fibrillation to prevent the formation of blood clots, thereby reducing the risk of stroke and systemic embolism.
Used in Vascular Medicine:
Edoxaban is used as a treatment for deep vein thrombosis and pulmonary embolism, helping to dissolve existing blood clots and prevent the recurrence of these conditions.
It is important to closely monitor patients taking Edoxaban for signs of bleeding, as with all anticoagulant medications, to ensure its safe and effective use.

Upstream product

• 480452-36-6 carbamic acid, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-1,1-dimethylethyl ester 
• 480450-69-9 tert-butyl N-[(1R,2S,5S)-2-azido-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate 
• 1072-98-6 5-chloro-2-pyridylamine 
• 929693-35-6 (1S,3S,6R)-N,N-dimethyl-7-oxabicyclo[4.1.0]heptane-3-carboxamide 
• 929693-36-7 (1S,3R,4R)-3-amino-4-hydroxy-N,N-dimethyl cyclohexanecarboxamide 
• 929693-30-1 (1S,3R,4R)-3-[(tert-butoxycarbonyl)amino]-4-hydroxy-N,N-dimethylcyclohexanecarboxamide 
• 929693-31-2 {(1R,2R,4S)-2-[(tert-butoxycarbonyl)amino]-4-[(dimethylamino)carbonyl]cyclohexyl}methanesulfonate 
• 365998-36-3 (1S,2R,4S)-N₂-(tert-butoxycarbonyl)-4-(N,N-dimethylcarbamoyl)-1,2-cyclohexanediamine 
• 5708-19-0 (1S)-3-cyclohexenecarboxylic acid 
• 480449-70-5 edoxaban 
• 104-15-4 toluene-4-sulfonic acid 

Relevant articles and documents

Method for the Preparation of Diamine Derivative

The present invention relates to high yield. The present invention relates to a process for preparing high purity ethaboxate p - toluenesulphonate or hydrates thereof. To the present invention, generation of a dielectric toxic substance and a side reaction product can be suppressed, and high yield, high purity of edoxaba p - toluenesulphonate or a hydrate thereof can be advantageously used.

Preparation method of edoxaban tosylate and isomers thereof

The invention discloses a preparation method of edoxaban tosylate and isomers thereof. By taking a compound (I) and a compound (II) as starting materials, the method can be used to prepare any one ofhigh-purity edoxaban tosylate (1S, 2R, 4S), edoxaban tosylate enantiomers (1R, 2S, 4R), edoxaban tosylate epimers (1R, 2R, 4S) and edoxaban tosylate epimers (1S, 2S, 4R). Effective guarantee is provided for process research and quality control of the edoxaban tosylate bulk drug and related preparations, the preparation method is suitable for commercialization, the produced edoxaban tosylate bulk drug is high in purity and has great significance and practical value, and the production of the edoxaban tosylate bulk drug and the control of drug quality are facilitated.

Preparation method of edoxaban

The invention relates to a new preparation route and a new method for a p-toluenesulfonic acid edoxaban hydrate and intermediates thereof. The new method comprises the steps that a high-reactivity compound 109A4x is prepared; a compound 109C6x is prepared by using a new synthesizing method; new compounds 109E8-01, 109E9x and 109T7-01 are prepared; the p-toluenesulfonic acid edoxaban hydrate is prepared by using the intermediates. By using the new method and the new route, the reaction step of copious cooling is omitted, and dangerous elemental sulfur, high-risk n-butyllithium and high-risk azides are prevented from being used. In a word, by means of the method, the p-toluenesulfonic acid edoxaban hydrate and the key intermediates thereof are more easily and safely prepared at a lower coston an industrialization scale.